Tofacitinib, sold under the brand name Xeljanz, is a Janus kinase (JAK) inhibitor used to treat conditions like rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis [1]. Pharmaceutical companies and patient assistance programs may offer coupons or discounts to help reduce the out-of-pocket cost of this medication [2].
How can I get a Tofacitinib coupon?
To find available coupons or savings cards for Tofacitinib, individuals can typically visit the official Xeljanz website or search for patient assistance programs. These programs are often designed to make prescription medications more affordable for eligible patients. Websites specializing in prescription discount cards may also list available savings [2].
What is the typical cost of Tofacitinib without insurance?
The cost of Tofacitinib can vary significantly depending on the dosage, quantity, and pharmacy. Without insurance, the retail price can be several thousand dollars for a monthly supply. For example, a 30-day supply of 11 mg tablets might cost upwards of $5,000, while a 30-day supply of 5 mg tablets could be around $4,000 [3].
Are there patient assistance programs for Tofacitinib?
Yes, Pfizer, the manufacturer of Xeljanz, offers a co-pay assistance program for eligible commercially insured patients. This program can help reduce out-of-pocket costs for those who qualify [2]. Information on eligibility and how to apply is usually available on the Xeljanz website.
How does Tofacitinib work?
Tofacitinib is a JAK inhibitor. It works by blocking the activity of Janus kinases, enzymes that play a role in the immune system's inflammatory response [1]. By inhibiting these enzymes, Tofacitinib helps to reduce inflammation associated with certain autoimmune diseases.
What are the side effects of Tofacitinib?
Common side effects of Tofacitinib can include upper respiratory tract infections, headache, and diarrhea. More serious risks include infections, blood clots, heart attack, stroke, cancer, and a torn stomach or intestinal wall [1]. Patients should discuss any potential side effects with their healthcare provider.
When does the patent for Tofacitinib expire?
Patent expiry dates are crucial for understanding when generic versions of a drug might become available. Information on the patent status and expected expiry for Tofacitinib can be found on resources like DrugPatentWatch.com [4]. Generally, the first Tofacitinib patent is expected to expire in 2025 [4].
Can I get Tofacitinib at a lower cost if I have Medicare or Medicaid?
Medicare and Medicaid beneficiaries may have different cost-sharing arrangements for prescription drugs. While a specific coupon might not apply directly, these government programs have their own formularies and cost structures. Patients should consult their Medicare or Medicaid plan details or contact the plan provider for information on Tofacitinib coverage and potential cost assistance.
How does Tofacitinib compare to other treatments for rheumatoid arthritis?
Tofacitinib is one of several treatment options for rheumatoid arthritis, alongside other JAK inhibitors, conventional synthetic disease-modifying antirheumatic drugs (DMARDs), and biologic DMARDs. The choice of treatment depends on individual patient factors, disease severity, and response to prior therapies [1].
Sources:
[1] https://www.fda.gov/drugs/postmarket-drug-safety-information-for-patients-and-providers/xeljanz-and-xeljanz-xr-tofacitinib-information
[2] https://www.xeljanz.com/savings-and-support.html
[3] https://www.goodrx.com/tofacitinib
[4] https://drugpatentwatch.com/p/tofacitinib